|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Amgen Valuation Now Excludes Potential Repatha Revenues [February 13, 2016]
FDA Approves Imlygic (T-vec) for Melanoma [October 27, 2015]
FDA Approves Repatha [Amgen press release August 27, 2015]
Why Amgen is a Biotechnology Portfolio Cornerstone [March 10, 2015 at Seeking Alpha]
2017 |
|||
April 26, 2017 |
July 25, 2017 |
||
2016 |
|||
04/28/2016 |
07/27/2016 |
10/27/2016 |
02/02/2017 |
2015 |
|||
04/21/2015 |
07/30/2015 |
10/28/2015 |
01/28/2016 |
2014 |
|||
4/22/2014 |
07/29/2014 |
10/27/2014 |
01/27/2015 |
2013 |
|||
Not available |
|||
07/30/2013 |
10/22/2013 |
01/28/2014 |
|
Amgen 2014 Business Review Notes October 28, 2014
Amgen initial purchase March 24, 2014
Amgen with Onyx Pharmaceuticals: Long Term Analysis September 4, 2013
Amgen Valuation [blog 12/3/2007]
I did not follow Amgen closely between the end of 2008 and mid-2013. I did own Onyx Pharmaceuticals during most of that time.
2008 |
|||
 |
|
|
|
Q3 2008 |
Q2 2008 |
Q1 2008 |
Q4 2007 |
10/22/2008 |
07/28/2008 |
04/24/2008 |
1/24/2008 |
2007 |
|||
|
|
|
|
10/24/2007 |
07/26/2007 |
4/23/2007 |
|
Q3 2007 |
Q2 2007 |
Q1 2007 |
|
Amgen is a biotechnology therapeutics company selling a variety of drugs, notably Arenesp, Epogen and Enbrel.
Amgen Web site:
Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but its possible. I am simply sharing my personal notes, not advising anyone about investments.
Copyright 2017 William P. Meyers